TransCode Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:RNAZ

Comments

TransCode Therapeutics Inc Earnings Estimates

RNAZNASDAQ

Trade with Public

$8.70

0.161.87%

At close: Mar 27, 5:00 PM EST

$8.60

-0.1-1.15%

After Hours: Mar 24, 9:20 AM EST

Overview NewsEarningsAnalyst Ratings Insider Trades Short Interest Stock Report

TransCode Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:RNAZ

TransCode Therapeutics (RNAZ) is scheduled to report Q1 earnings on May 13, 2026.

TransCode Therapeutics has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, TransCode Therapeutics has averaged an EPS surprise of 15.88% and a revenue surprise of 1.00%.

Earnings Date

Nov 14

EPS

$-5.820

Quarterly Revenue

$0.00

Annual Revenue
(as of Sep 30)

–

TransCode Therapeutics Earnings History

Analyze the earnings history of TransCode Therapeutics using advanced sorting and filters.

Loading calendar...

TransCode Therapeutics (RNAZ) Earnings Per Share

The chart below shows TransCode Therapeutics's reported EPS compared to analyst estimates over recent quarters.

TransCode Therapeutics (RNAZ) Revenue

The chart below shows TransCode Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is TransCode Therapeutics (NASDAQ:RNAZ) reporting earnings?

TransCode Therapeutics (RNAZ) is scheduled to report earnings on May 13, 2026. The last reported earnings were for reported on November 14, 2025 for Q3.

What were the latest earnings per share (EPS) for TransCode Therapeutics (NASDAQ:RNAZ)?

The Actual EPS was $-5.82, which missed the estimate of $0.00.

What were TransCode Therapeutics’s (NASDAQ:RNAZ) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

CANF

Bolt Biotherapeutics Inc

NASDAQ:BOLT

$4.76

8.68%

BioRestorative Therapies Inc

NASDAQ:BRTX

$0.32

8.01%

AlphaTON Capital Corp

CollPlant Biotechnologies Ltd

NASDAQ:CLGN

$0.60

-3.62%

TransCode Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:RNAZ

TransCode Therapeutics (RNAZ) is scheduled to report Q1 earnings on May 13, 2026.

TransCode Therapeutics has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, TransCode Therapeutics has averaged an EPS surprise of 15.88% and a revenue surprise of 1.00%.

Earnings Date

Nov 14

EPS

$-5.820

Quarterly Revenue

$0.00

Annual Revenue
(as of Sep 30)

–